IP Library Granted Patent US 11,918,271
Granted Patent B2
US 11,918,271 · App. 16/906,979 · Granted Mar 5, 2024

High-voltage pulse ablation systems and methods

Inventor: David K. Swanson (Campbell, CA)
Assignee: AtriCure, Inc.
A61B18/085A61B18/08A61B18/10A61B18/1206A61B2018/00351A61B2018/00363A61B2018/00392A61B2018/00577A61B2018/00613A61B2018/00654A61B2018/00702A61B2018/00797A61B18/06A61B2018/145A61B18/1815A61B18/20A61N2007/025
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,918,271
App. No.
16/906,979
Granted
Mar 5, 2024
Kind
B2
Abstract

High-voltage pulses ablation systems and methods are used to ablate tissue and form lesions. A variety of different electrophysiology devices, such as catheters, surgical probes, and clamps, may be used to position one or more electrodes at a target location. Electrodes can be connected to power supply lines and, in some instances, the power to the electrodes can be controlled on an electrode-by-electrode basis. High-voltage pulse sequences provide a total amount of heating that is typically less than that which is observed with thermally-based radiofrequency energy ablation protocols.

Claims (15)

1. A method of administering an ablation treatment to a patient's skin, the method comprising:

placing a return pad at a location on the patient's skin;

placing an ablation assembly at a patient target tissue having a tissue thickness, the ablation assembly comprising a first electrode mechanism and a second electrode mechanism, wherein the first electrode mechanism and the second electrode mechanism are spaced linearly along the ablation assembly, wherein the first electrode mechanism and the second electrode mechanism each comprise one or more coagulation electrodes and one or more stimulation electrodes;

applying a high voltage pulse regimen to the tissue between the first electrode mechanism and the second electrode mechanism with the ablation assembly, wherein the pulse regimen comprises a plurality of 1000-2000 volt pulses each having a duration of between about 0.02 msec and about 0.1 msec, and wherein the pulses are delivered by the stimulation electrodes at a frequency comprising a pulse number within a range from about 5 to about 50 pulses discharged over a time interval within a range from about 1 to about 60 seconds; and

creating a lesion within the patient target tissue, the lesion having a width of about twice of the tissue thickness.

2. The method according to claim 1 , wherein the patient tissue comprises a plurality of myocardial cells, and the ablation treatment is sufficient to kill at least a portion of the plurality of myocardial cells located within about 5 mm of either of the first electrode mechanism or the second electrode mechanism.

3. The method according to claim 1 , wherein the patient target tissue comprises a plurality of myocardial cells, and the ablation treatment is sufficient to irreversibly damage the plurality of myocardial cells.

4. The method according to claim 1 , wherein the high voltage pulse regimen comprises multiple volt pulses each having an amplitude of about 1000 volts and a pulse width of about 0.05 msec.

5. The method according to claim 4 , wherein the high voltage pulse regimen is sufficient to ablate the patient target tissue to a depth of about 5 mm.

6. The method according to claim 1 , wherein the high voltage pulse regimen comprises multiple volt pulses each having an amplitude of about 2000 volts and a pulse width of about 0.05 msec.

7. The method according to claim 6 , wherein the high voltage pulse regimen is sufficient to ablate the patient target tissue to a depth of about 10 mm.

8. The method according to claim 1 , wherein the patient target tissue has a thickness of about 10 mm and the ablation treatment is sufficient to create a lesion within the patient target tissue, the lesion comprising a substantially semicircular cross-section.

9. The method according to claim 1 , wherein the tissue thickness is about 4 mm and the lesion width is about 8 mm.

10. The method according to claim 1 , wherein application of the high voltage pulse regimen results in little or no cellular damage in the patient's skin near the return pad.

11. The method according to claim 1 , wherein application of the high voltage pulse regimen results in a voltage gradient of about 10 V/cm or lower at the patient's skin near the return pad.

Assignments (3)
SECURITY INTEREST Recorded Jan 10, 2024
From: ATRICURE, INC.; ATRICURE, LLC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 066267/0896 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2020
From: SWANSON, DAVID K.
To: ENDOSCOPIC TECHNOLOGIES, INC
Reel/Frame 052994/0034 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2020
From: ENDOSCOPIC TECHNOLOGIES, INC
To: ATRICURE, INC.
Reel/Frame 052994/0294 →